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b t ract 
Warfari n i the most common! used oral anticoagulant medication given as a 
proph) laxis and/or treatment of enou and arterial thromboembol ic disorders. 
\Varfarin do e \ ary up to l O-fold among pat ients due to pharmacok inetics, 
pharmacodynamic and pham1acog nomics [actors. I n  addition, Warfarin has a low 
therapeutic index \vith the ri k of de eloping serious side effects such as severe 
bleeding or fai lure of therap . Therefore, the main chal lenge to ach ieve the 
therapeut ic goa l in Warfarin treatment i estimating the appropriate dose [or each 
pat ient. I t  i estimated that pharmacogenomic factor contribute to more than 60% of 
dose variab i l i ty .  The gene encoding for the target enzyme of Warfarin, vitamin  K 
epoxide reductase complex 1 (I 'KORCl), is a highly polymorphic gene and 
contributes to about 30°'0 of this variabi l i ty. The US Food and Drug Administration 
(FD ) recommends genetic testing to determine the VKORCl genotype prior to 
using Warfarin .  Howe er, there are no data on VKORCl a l le les and genotypes or 
their frequenc ies among Emiratis. Therefore, the current approach is trial and error 
with warfarin do es which might lead to some serious compl ications for patients 
receiving this medication. In this thesis, we used peR ampl ification and direct DNA 
Sanger sequencing to genotype the two most important  variants in  VKORCl genes 
(namely, rs992323 1 and rs7294) .  The sample consisted of 1 1 7 healthy Emirati 
nationals as control and 96 patients on stable Warfarin therapy . The a l le les and 
genotypes frequencies were determined for both groups. I n  addit ion, the dai ly  
Warfarin maintenance dose for patients was examined for associations wi th the 
VKORCl genotypes at the rs992323 1 and rs7294posi tions. There was no significant 
di fference in a l le le frequencies between the controls  and patients for either SNP .  The 
Vll 
genot) pes frequenc ie for r 992"23 1 \\ ere 25° '0. 48 .4%, 26° 0 f, r GG. GA. AA 
genot) pes. re pective ly .  In addi tion. genotypes frequenc ies for rs7294 variant were 
44° '0. 44°0. 1 2�0 D r GG, G . A genot) pes, respecti e ly .  Crucial ly, both T'KORC 1 
poly morphi m were found to be strongly assoc iated with the Warfarin doses 
requi red to achieve the target internat ional nom1al ized ratio I R ( p  < 0.000 1 ). The 
result of thi study con fi rm the suitabi l i ty of VKORCl genotyping to guide the use 
of the appropriate arfarin  dosage for Emirat is. 
Ke,,\\ ord : Warfarin dosage, r 992323 1 ,  r 7294, VKORCl, phalmacogenet ics of 
Emiratis. Phannacogenomics 
Title a n d  b t ract ( i n  Arabic) 
\'111  
�1..;Lo)l1 �I.JA 0:: r 7294.J r 992323 1 ��I � VKORCI � �I .bL..�.i'il ..l� 
e,j.J"')J,JI ..;1Ac �..?- � .illj �1�t:i.J 
�..? � VK R 1 r.!Y\.} �I u\�I.J:!-'t A.....-I..;.l,l cill.).J �I ��� � �\..;.ll  .� 
u\�1 �l ..l..lji �y.-J �L...)\ o� �.J �.j-.d\ ulji;.:ill C)6J t=>L.::. �1.J..l �.J l>.!"}J�1 .Jlic. 
�y> LJ.c J5 .} �I .bk;)l1 o� ..r.?Li � A.....-1.J..l.J ul) . .o'J'1 �.J..l �Iy> .} r.!Y'J'\ I� .) �I 
M �Y.J 117..l.k. �l.:.......::,\ ,j-fj)...,'J' u� � w....:i �I J..= ��.J rs7294 j rs9923231 
ii f.l.ll u� ��.J A.....-\.J.l.I� LJ:!SJ .. :.: .. .JI ..l1..}'J' I :W\y> � cill.).J 96 ..l.k. l>.!..})}\ .J\.i..., �)lc. 
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.J % 25.3 � GG J �I.b.d\ ..l..lji 01S j rs9923231 �y>.} �1.bk;'J'1 ..l..lji �..?-A.! �L...)I 
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H PTER 1 :  I TRODUCTI O  
1 . 1  H u ma n  G enet ic Va ria t ion a n d  Drug Re pon e 
Int r-indi  idual variation in drug re pon e and the deve lopment of drug side effects 
among pat ient ar major chal lenge in c l inical pharmacology. everal factors 
usua l l} contribut to this variabi l ity inc lud ing age, weight, Ie el of organ function, 
CO-J11 dication , di t!a e itse lf, concomitant d isease , cul tural and racial factors 
inc lud ing genetic , moking. alcohol consumption and dietary preferences [ 1]. 
However, for some medicat ions, the genetic variat ion is  the major contributor with 
up to 9500 in some ca e [2]. 
II humans ar gen tical ly  identical in about 99% of their genomes. The 
approximately 10'0 d ifferences from person to person are mainly in the fonn of 
ingle nucleotide polymorphisms ( Ps), copy number variations (C Vs) and 
variation in the number of tandem repeat [ 3].  A SNP is a change in the sequence of 
a single nucleotide base [ 4]. On average, a S P appears e ery 1 250 bp of DNA in the 
human genome and they account for about 90% of human genetic variation [3]. 
General ly,  there are numerous polymorphic variants for most genes among the total 
world population and consequent ly it is  often hard to know which variant is  the 
" true" wi ld  type sequence [5]. 
S Ps in coding gene of drug metabol izing enzymes, drug receptors, drug binding 
proteins and drug transporters may cause variabi l i ty in the structures andlor act iv i t ies 
of the encoded proteins [4]. In addit ion, in some instances SNPs in genes encoding 
drug-metabol i zing enzymes or proteins involved in handl ing med icat ions may resul t  
In lo\\ er mR expres IOn and h nce may cau e lo\\ er enzymIc activity or 
alterati 11 in  receptor function [ 6 ] .  On the oth r hand, dupl ication or mult ipl ications 
of active gene re ult in high r mR A level and thus higher enzyme expression 
that lead to an increase in enz) mic activity and faster metabol ism of the medications 
handled by that part icular enzyme [6 ] .  
NPs are re ponsible for a large proport ion of thc genet ic contribution to variation in 
drug re pon e and therefore the are key targets for pharmacogenetic s and 
pha1111acogenomics stud ies [-+] .  
1 .2 P h a rm acogenet ic  and Pharmacogenom ics 
Pha1111acogenetics i the inherent response or the genetica l ly  determined variation in  
dmg response. ccord ing to the F DA definit ion, i t  is the study of variation in DNA 
sequences that can affect drug response . Recently, the d iscipl ine of 
"phannacogenomics" has been defined as the study of variation in DNA sequences 
and RNA characterist ics at the whole genome level that can affect drug response. In 
other words phamlacogenomics deals with inter- individual variation at whole 
genome level with specific expression products and functions that can be used to 
predict the appropriate treatment for i ndividual pat ients [7 ] .  To simpl ify the 
d ifference between phannacogenetics and phannacogenomics, phamlacogenetics can 
be defined as the effect of inter- indvidual d ifferences caused by variation in  a single 
gene whereas phannacogenomics relates to the i nvolvement of many genes or the 
whole  genome in the variab i l i ty in dmg response [7 ]  
.., -' 
T reiterate, genetic variation in genes encoding dnlg metabol izing enzymes, drug 
tran p rter , drug-binding prot ins and receptors can a l l  cause variat ion in the 
phenotypic re pon e and thus are key targets for studying the pharmacogenetics and 
pharmacogenomics of most medications [ 8 ] 
Mo t effort t tud the involvement of genetic variation on dose requi rements and 
re ponse of pat ients to drugs were carried out as a result of ad erse drug reactions 
and side effects. These adverse drug reactions are estimated to be the 4th or 6th 
leading cause of death in the USA and to be the underlying cau e of approx imate ly 
1 0% of inpat ient admissions to hospitals .  It has been estimated that approximately 
2.2 1 6,000 patients suffer from serious side effects of medicat ion leading to an 
estimated 1 06.000 pat ient deaths in the USA alone [9 ] .  I n  the U K, adverse drug 
react ions cost approximately £ 3 80 m i l l ion a year. I n  addit ion, an NIH report 
indicates that one out of ten inpatient admissions are for cases of adverse drug 
react ion [ 1 0] .  
tudy carried out in Saudi Arabia showed that healthcare professionals lack the 
awareness of the i mportance of record ing adverse drug react ions and ana lyze related 
the outcomes [ 1 1 ] . Another Study carried out in the United Arab Emirates (UAE) 
concl uded the prevalence of inadequate knowledge of adverse drug reaction 
reporting procedures as a major barrier in recording adverse drug reactions [ 12 ] . 
More than 50% of adverse drug reactions relate to an administered dose [ 1 ]  and 59% 
of drugs metabol ized by polymorphic enzymes have been reported to have serious 
adverse effects [ 1 3 ] .  
Theref re, pharmac genetic and pharmacog nomic studies aim to reduce the ri k of 
med ication u age b predicting the optimal do e and the risk of developing side 
effect a ociated with particular medication in individual patients. In  other words, i t  
a im t ident ify patients at ri k of developing adverse side effects by determining 
their genetic variant in the genes relevant to the proscribed med ication [ 1 4].  
Over the ears, the genet ical ly determined variation in drug response has become 
10 reasingl recognized by physic ians. geneticists and pharn1aceutical researchers. 
Therefore, there i an urgent need for pharmacogenet ics and pharmacogenomics 
re earch to det rmine the appropriate dose for each patient . Consequent ly, 
pharn1acogenetic testing may open the door for physicians to pred ict optimal doses 
and re pon es to individua l  med ications given to patients. 
1 .3 Wa rfa rin: Historical  Overview, Action M ec hanism, Cl inical Appl icat ions 
and As ociated Side Effects 
In  the early 1 920s, an outbreak of unknown cattle d i sease was observed in the United 
tates and Canada. Severe spontaneous hemorrhages occurred to catt le and some 
died after castration or dehorning. Prior to that, these procedures had been perfoD11ed 
with no of excessive bleeding. I nvestigation autopsies of dead animals revealed that 
the animals bled to death [ 1 5]. One year later, a Canadian veterinary pathologist 
cal led Frank Schofield attributed the cause of death to the ingestion of hay made 
from spoi led sweet c lover. Subsequent experimental testing on rabbi ts determined 
that spoiled c lover worked as a potent ant icoagulant [ 1 5].  
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In 1 929, another veterinarian cal led L.M. Roderick investigated the cau e of bleeding 
and sugge ted that it wa caused b the decrea e in the [unct ion of prothrombin [ 1 6] .  
ub  equent ly, Henr ik  Dam from Denmark discovered that vitamin K deficiency can 
cause a hemorrhagic disease in chickens \ ith lower prothrombin levels simi lar to the 
ca es rep rted in catt le in orth America [ 1 7] .  everal year later, a trial was 
performed to make potent toxins out of spoi led weet clo er at Wisconsin University 
[ 1 8 ] .  In part icular, in 1 933 Karl Paul Link and his  team were able to isolate the toxic 
hemonhagic substance [ 1 9] .  L ink and his group also ident i fied the chemical structure 
of thi compound as 3, 3 , -Methylene-B is-(4-Hydroxycoumarin) [ 20] . L ink later 
nam d thi compound Dicoumarol ,  which is a fermentation of the plant molecule 
Coumarin [ 2 1 ] , that is present in many plant and gi es the sweet smel l  of fresh grass 
and hay. I nterestingl , the name "sweet c lover" comes from i ts higb content of 
Coumarin [ 1 8] .  
The Coumarin molecule itse lf  has no anticoagulant properties but this activity results 
from i ts fermentation by fungi .  L ink donated the patents for Dicoumarol to the 
Wisconsin Alumni Research Foundation ( WARF) in 1 939 and continued his work on 
de\'e loping potent ant icoagulants to be used as rat poison [ 2 1 ] . I n  1 940, he was able 
to ach ieve his goal with the most potent rodentic ide which he named "Warfarin" 
[ 2 1 ] . I t  was bel ieved that Warfarin would  be extremely toxic  to humans as wel l  as 
rats unt i l  suicidal attempts in 1 952  ended up with hospita l ization fol lowed by ful l  
recovery of the pat ient. Crucial ly,  the pat ient was treated with Vi tamin K to 
antagonize the effect of Warfarin [ 22 ] . Further studies demonstrated the possible use 
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of Warfarin a a treatment in coagulation condition [ 2 1 ] .  umerous studie were 
an"ied ut to e tabl i  h the e'<.act effects of Warfarin on humans [22 ] .  
Rep rt of variable re pon e b human to  fixed doses of Warfarin were 
documented very early after its ini t ia l  use [2 3 ] .  Today Warfarin is the mo t widely 
pre ribed oral ant icoagu lant worldwide due to its effecti eness. low cost and 
cOll\ enient oral  dose [ 24]. 
Vi tamin K play a role in the coagulation cascade since the reduct ion of vitamin K 
lead to the activation of c lotting factors through the gama carboxylation of these 
coagu lation proteins most ly  factors I I  ( Prothrombin), V I I , I X, X, protein C and 
Protein S.  nderstandabl . these proteins are cal led V itan1in K dependent proteins. 
Once they are carboxy lated, they get transformed into their active forms that lead to a 
coagulation cascade [25 ]  . 
Vi tamin K reduced by Vi tamin K expoxide reductase ( V KOR) functions as a 
recycl ing enzyme for V i tamin K.  The basic action mechanism of Warfarin is  the 
inhibi tion of Vitamin K expoxide reductase (yKOR) enzyme and thus the impairing 
of the synthesis of c lotting factors [26] as i l lustrated in Figure 1 .  
actors II. VII, IX. X 
Proteins C, S, Z 
Warfarin 
OxidisCd vitamin K 
{Factors II. VII, IX X 
Achvat�d 
Proteins C S. Z 
Figure 1 .  Effect of Warfarin on V KO RC acti i ty and V itamin K cyc le .  [26].  
7 
There are two isomer forms of Warfarin, the S and the R i somers as shown in  Figure 
2. The - isomer is five t imes more potent than the R-isomer in inh ibit ing V KORC 
[ 2 5]. 
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(A) S -Wa rfa rin ( B )  R- Wa rfa rin 
Figure 2. Molecular Structure of (A)  S -Warfarin and ( B  R- Warfarin. [27]. 
The effect of  Warfarin therapy on a blood coagulation profile i s  measured by the 
International ormal ized Ratio ( INR)  which is a universal con ersion of 
prothrombin t ime test [28].  
9 
In 1 990, the 1 R wa adopted as an indi cator to mon itor Warfarin effects. INR 
corrects for ariation that come \ :  i th  di fferent thr mbopJastin reagents from di fferent 
ho pital and laboratorie \\ orldwide, and for new batches of reagent [29]. 
To a\ oid h 111 rrhage ( the princ ipal  adverse side effect of Warfarin), frequent 
mon itoring and adjustment to the anticoagulant effect of the drug is necessary. 
This depend on the I R result which can be obtained by a Prothrombin Time test 
(PT te t) for monitoring and eval uating the effect of vitamin K antagonist (VKA)  
therapie and i a re l iable measure of extrinsic pathways of coagulation [29] ,  [30]. 
In order to achieve treatment goal s  with anticoagulation therapy using a Vitamin K 
antagonist such as Warfari n, patients need to maintain their target I N R  range. This 
goal can be achie ed \ i th regular monitoring and appropriate adjustment to a 
Warfarin do e [30] .  Target I N R  inter a ls vary according to Warfarin indication, but 
in general an I R value of <2.0 is assoc iated with increased risk of a thrombotic 
event whi le I N R  alue o f  >4.0 i s  assoc iated with increased risk o f  a bleeding crisis. 
Therefore, current recommendations suggesting an I N R  range of between 2 .0 and 3 .0 
for patients with atrial fibri l l at ion and venous thromboembol ism [30] [ 3 1] and an 
I N R  range of 2 .5 -3 . 5  for patients with mechanical heart valves [32].  
Warfarin does not exert an instant effect as an antithrombotic/anticoagulant 
medication as several doses are required to show an effect. The delayed effect is  due 
to pre-exist ing V itamin K-dependent c lott i ng factors that must be catabol ized by the 
body willie at the same t ime i nhibit ing the activation of newly made V itamin  K­
dependent c lott ing fac tors and for total protection from thrombus fomlation or 
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compl ication . Howe er, the ora l ly  admi nistered anticoagulant Warfarin can be 
given with a rapid act ing ant icoagulant such as Heparin or Low Molecular Weight 
Heparin [ 30 ] .  
Warfarin j an oral anticoagu lant that is mostly prescribed to prevent the progression 
or recurrence of acute deep vein thrombosis or pul monary embo l ism as a second 
option a fter using Heparin. I t  is a lso used to prevent venous thromboembolism 
during surgerie such as Olthopaedic or gynecologic surgeries and as a prophylactic 
treatment in chronic atrial fibri l lation, acute myocardial infarct ion, prosthetic heart 
valve and troke [29],  [ 3 1 ] . 
Although it i s  widely used, Warfarin has one major limitation. I t  is a drug with a low 
therapeutic index and is l i sted among the top 1 0  agents associated with serious s ide 
effects such as bleed ing. Approximately 20% of patients using Warfarin suffer from 
bleeding, thromboembol ic  events (TEE), inpatient hospita l ization and emergency 
admission or sometimes treatment fai l ure and the compl ication of coagulation. I t  
should a lways be given with safety contro ls  as indicated on the drug labe l [29] ,  [ 33 ] .  
Besides hemorrhages, other minor side effects have been observed such as  skin 
lesions and necrosis .  Another problem assoc iated with Warfarin use is  the numerous 
drug-drug interactions and its teratogenic effect. Therefore, Warfarin should never be 
used during pregnancy due to associated birth defects and abortion [ 29 ] .  
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l A  Factor Influencing Variab i l ity in Wa rfa rin Do e Req u i rement 
ariabi l i ty in warfarin dose has been e ten i e ly documented. This variabi l ity can 
be attribut d to combination of gen tic and non-genetic factor as detai led in the 
fol lo\\.. ing ection . 
l A. 1  on-Genet ic  Factor 
alread mentioned. Warfarin is a drug with a low therapeutic index and therefore, 
mal l  increases in do age may cause serious side effects whi le a 10\ er than 
therapeutic dose wi l l  b ineffective.  Maintenance doses of Warfarin requi red to 
afely ach ieve stable anticoagulation can vary across populations by up to twenty 
fold \\ i th an average dose of 5 mg/day . However, some individuals require doses of 1 
mg/da, or les whi lst other may requ i re up to 20 mg/day or e en more to achieve 
the desired I R target [29]. The identification of the maintenance dose is important 
to avoid the risk of bleeding that comes with Warfarin use, depending on the co­
morbid condit ions of the pat ient [34].  Sign ificant efforts and research have been 
undertaken to avoid the development of side effects by estimating the exact safe 
dosage as Warfarin is the most often c ited reason for mortal i ty caused by medication 
[ 33]. It is  a lso the second leading cause of drug emergency admissions in  the Uni ted 
States [ 35 ] .  I t  is worth noting that the most often c i ted l i fe-threatening compl ications 
of Warfarin use are gastrointestinal b leeding and intracranial hemorrhage [36].  
Many co-medications can change the required dose of Warfarin and the mam 
mechanism is e ither by induction or inhibition of hepatic CYP2C9 or by competition 
with the p lasma protei n  binding s i te for Warfarin [29] . Drugs that can i nduce the 
expression of C Y P2C9 cause an i ncrease in  the enzymic action of CYP2C9 and 
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po ibl)- the induction of other metabolizing l iver enzymes [ 3 7 ) .  examples of such 
drug include alcohoL barbiturates. glutethimide, grisoful in, rifampin, 
carbamazepine. phenobarbital .  phenytoin and the herbal antidepressant st. john ' s  
wort . hron ic alcohol consumption has the ame action on CYP2C9 enzymic 
induction [29]. Patient US1l1g enzyme inducer drugs along with Warfarin require 
higher do e of Warfarin [ 38]. 
Other medication may cau e the opposite effect on the CYP2C9 enzyme as they may 
inh ibit  its catalytic activity [ 3 8 ] .  For example. azo le  ant ifungal medicat ions (e.g. 
fl uconazole and voriconazole). amiodarone, sul famethoxazole  (found in the common 
combination anti biotic trimethopri m-sulfamethoxazole), statins (e .g .  fluvastat in and 
100 astatin). and some antidepressants (e .g.  fluvoxamine and sertraline), cimitdine, 
chloramaphenicoL cotIimoxazol ,  d isuulfiram, metronidazole, phenylbuazone, and 
acute alcohol intoxication a l l  have inhibitory effects on CYP2C9. Patients using a 
CYP2C9 inhibitor medication concomitantly with Warfarin need lower doses of the 
anticoagulant since the metabolism and the evacuat ion of Warfarin wi l l  be reduced 
as a resul t  of the decrease in CYP2C9 function and thus increase the risk of an 
accumulation of Warfarin to toxic levels .  I n  these cases, anticoagulant overdose is a 
major ri sk. I n  terms of drug-drug interactions among a l l  these medications, the drugs 
with a strong effect on Warfarin dosage are amiodarone and statins [ 39] , [40],  [29] . 
I n  order to predict Warfarin dosage the Warfarin dosing websi te 
(www .warfarindosing.com) developed an online calculator that takes into account 
possible factors that can cause changes in Warfarin dosage especial ly concomitant 
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therap) \>\ ith amiodarone, latin , azole ant ifungals, sul famethoxazole and 
trimcthoprim as factors to predict the most appropriate Warfarin dose [ 29 ] . 
Vitamin K d {iciency, a hepatic disea e that impair  a synthesis of c lotting factors, 
an, di ea e or medication that can impair organ function that controls  Warfarin 
metab Ii 01 ,  or a hypellTIetabol ic tate that elevates Vitamin K leve ls  depending on 
c lotting factors and catab Ii 01 are a l l  factors that can contribute to a 
h) popr thrombinemic tate in patients and therefore the affect the required dose 
[ 29] .  
Warfarin i a water soluble molecule that i s  quickly absorbed after oral intake with 
peak plasma concentrat ion obtained from 60 to 90 minutes and 1 00% bioavai labi l ity 
with l i tt le indi\' idual variation in bioavai labi l i ty .  However, food may delay 
absorption without affecting the extent of absorption and 99% is  bound to plasma 
albumin and drugs with a higher affinity to a binding s i te for albumin l i ke 
u l fonamides that can displace Warfarin from Plasma albumin leadi ng to an 
e levation of Warfarin activity [29] . I n  addit ion, Lovastatin  and I ndomethacin  
compete with Warfarin for plasma protein bind ing s i tes and therefore increase the of 
free activity of Warfarin and potentiate its action [ 29 ] .  
1 .4.2 Genet ic  Factors 
There are several genetic factors that can affect a patient ' s  Warfarin dose. 
Polymorphisms in cytochrome P-450 C9 (CYP2C9), the enzyme responsible for 
Warfarin metabol ism are major contributors. However, it was est imated that genetic 
variation in the gene encoding for this enzyme account for approximately 1 2% of the 
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changes in the maintenance dose of Warfarin [ 4  J ] , [42 ] .  I n  addition, genetic variation 
f r 'KORCI. the gene encoding Warfarin ite of action ( V itamin K Epo. ide 
Reductase), account for up to 30% of the inter- individual ariation in maintenance 
dose [43 ] .  [44 ] .  More deta i ls  on the contribution of VKORCland CYP2C9 wi l l  be 
pro\ ided in the next ection ( 1 . 5 . ) .  
Re  earchers attempted to ident if  other genes invo lved in the dose variation of 
Warfarin among individuals identified CYP-IF2 as a contributory factor to variations 
in do e .  The CYP4F2 enzyme is \ idely distributed in human l ivers and other ti ssues. 
I t  function i s  to  catalyze the hydrox lation of L ipox genase-derived eicosanoids as 
wel l  as the oxidation of Vitamin K [45 ] .  A genetic variat ion in CYP-IF2 that results 
in  the replacement of a val ine amino ac id at position 433 by methion ine (p .V 433M)  
leads to  a decrease in  the oxidation of V itamin K.  This i n  tum causes an  elevation in  
the  concentration of i tamin  K in  hepatic cel l s  and therefore pat ients on  Warfarin 
with this variant needs higher doses [46 ] .  The total effects of C YP -I F2 on Warfarin 
dosage accounts for about 1 -2% of the change in  dose among individuals [47]-[49] . 
tudies on GGCX gene found a correlation of a microsatel l i te variant with Warfarin 
sensit ivity [26] .  This enzyme has a cri tical role in  the vi tamin K cycle as i t  catalyzes 
the gamma carboxylation of vi tamin K dependent proteins in the coagulation cascade 
as shown in F igure 3 .  
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Figure 3 .  Role of y-glutamyl carboxylase (GGCX) i n  V itamin  K cycle [50] .  
GGCX catalyzes the posttranslational carboxy lation of specific glutamic acid 
residues to y-carboxyglutamic acid (gla) i n  a variety of vi tamin K-dependent 
proteins [50 ] .  
This  gene is located on chromosome 2 and encodes for gamma-glutamyl carboxylase 
enzyme (GGCX). Variants in GGCX require about 6% reduction in Warfari n  dosage 
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and the total effect of GC A gene accounts for < 1 % of the variation in Warfarin dose 
requirement [ 5 1 J . 
Genotype information and c l i nical factors such as age and weight are important 
predictor in Warfari n do ing calculation to select the optimal dose for the patients 
at the stmi of therapy [ 52 ] .  
d i fferent V itamin K intake for each patient i s  a lso a factor in Warfarin sen it ivity 
and resi tance. A high intake of vitamin K reduces the response to the med ication 
[ 5 3 ] .  I n  general ,  Vitamin K re fers to a fami ly of vi tamins K 1  ( Phyl loquinone) and K2 
( lenaquinone) that ar mainly involved in human health and disease [ 54 ] .  V itamin 
K l  come from dietary sources such as the green leaves of some vegetables, 
egetable oi ls  and supplements. The majority of Vitamin K stores in the human body 
consist of V itamin  K l  [ 55 ] .  
I n  addi tion. gut bacteria synthesize V itamin K2 which has a l imi ted role in  providing 
the human body with dai ly requirement of V itamin K i n  comparison to Vi tam i n  K l . 
There are four main fat soluble itamins (A,  0, E and K).  Vitamin K has the lowest 
total stores in the body hence several weeks of restricted dietary intake of V itamin K 
can completely deplete a l l  the V itamin  K stores in  the body [ 5 3 ] .  Studies on the 
effects of different V itam in  K intake leve ls  on Warfarin requirements found that i t  is 
a s ignificant contributor to variation in the i ni tial Warfarin dose [ 56 ] .  
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1 .5 The Pharmacogenet ic a n d  Pha rmacogenomic of Wa rfar in  
1 .5. 1 Cytoc h rome P-'50 E nzyme 
1ctabol ic e l iminati n of mo t current drugs is  largel med iated by the function of 
C) tochrom P..J.50 protein . Thi enzyme system is encoded by many genes. The 
enz) me express d are mainly found in the l i ver and the play ke roles in drug and 
other xenobiotic metabol isms [57 ] .  The C YF syst m is very important for the 
det x i fi ation proce s as it e l iminates foreign sub tances. I n  addit ion to their 
invol\ ement in the metabo l i  m of l ipophi l ic  compounds i nvolving oxidation, the 
Y P  s)' tem is involved in the metabol ism of endogenous substrate such as sterols, 
teroid , eicosanoids, serotonin, bi le acids, V i tamin D, ret inoid, fatty ac ids and 
uroporphyrogens [57 ] .  
I n  every species there are 270 cytochrome P450s (CYPs) .  However, only 5 7  CYP 
genes and 33  pseudogenes are found in the hlmlan genome . These are organized in  
1 8  fami l ies and 42 subfami l ies. of a l l  the CYP fami l ies only 3 fami l ies ( fami l ies 1 ,  2 
and 3 )  are responsible for drug metabol ism.  CYP2C9 constitutes approximately 
1 8% of  the total CYP protein content i n  the human I i  er [38 ] ,  [ 58 ] .  
CYP2C9 is  one of the most important enzymes in  drug metabol ism as  i t  metabol izes 
approximately  60 drugs. There are i nter-ethnic and inter-individual variations in drug 
metabol i sms with the occurrence of genet ic polymorphisms in the CYP2C9 gene 
[59]-[6 1 ] . CYP2C9 is involved in the metabol ism of 1 0-20% of al l  the c l i ni cal ly 
important drugs worldwide such as Warfarin and other cotm1arin anticoagulants, 
losartan tolbutamide, sulfonylurea drugs angiotensin ii blockers, nonsteroidal ant i ­
inflammatory drugs (NSAI DS),  Phenytoin and g l ipizide [47] ,  [60] ,  [6 1 ] . 
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There are four d isti nctive group of CYP phenotypes arranged according to their  
metabol ic capac it) . E ten ive metabol izer (EM)  with regular metabo l ic capac ity, 
low metabol izer ( LM )  w ith low metabol ic activity, intermediate metabol izers ( 1 M )  
that hows intermediate activity, \ hi le  the ultra-rapid metabol izers C U M )  show the 
highe t metabol ic  act ivi ty group [6_ ] .  
C TP _ C9 polymorphi m s  are important detel1l1 inants o f  the Warfarin dosage as the 
pre en e of CYP2C9 polymorphi ms i a soc iated with a reduction in  the metabol ism 
of -Warfarin [63 ] ,  [ 64 ] .  Thi rty four CYP2C9 variant a l le les have been reported in 
the \-\-orId population 0 far (http://ww\V.cypaUe les .k i . se/) . CYP2C9* 1 i a wi ld-type 
al le le ,  and there are two important single nuc leotide variations that result in missense 
mutation in the coding region of the C YP2C9 gene. The CYP2C9*2 al lele (C430T 
in  exon 3 )  re u l t  in  the replacement of an arginine at  the amino ac id posit ion 1 44 by 
cysteine (p. R 1 44C). 
This is  a flllctional ly  important substitution as this mutation leads to the reduction of 
the catalytic act iv i ty to 1 2% compared to the wi ld-type enzyme. Additional ly, the 
CYP2C9*3 al le le (A I 075C of exon 7) leads to the substitution of a leuc ine residue 
by isoleuc ine at posit ion 359  (p .L359 I ) .  This mutation is assoc iated with a reduction 
in  the catalyt ic acti i ty to about 5% of the wi ld type. Studies have shown that the 
CYP2 9*3 al le le is  assoc iated with lower intrinsic c learance of the Warfarin 
substrate and a lesser enzyme act ivity « 5%) than C Y P2C9*2.  Both CYP2C9*2 and 
*3 genetic variants are widespread i n  caucasian populat ions, with al le le frequencies 
varying from 3 .3% to 1 8% [65 ] ,  [ 66] . 
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ab v , both TP 2C9* 2 and * 3  variant encode for enzymes with reduced 
catalytic activit ies that resul t  in impaired hydroxy lation of Warfarin compared to the 
\\ i ld-type CYP2 9 enzyme. Therefore, 10\ er do es of Warfarin are required in 
indi\' idual with th e al lele . It was ob erved that a longer t ime is required to 
achieve a table Warfarin do age and therefore these patients are at higher risk 
during the ini t ia l  phase of Warfarin therap [47] .  [ 63 ] .  
I n  cauca ian populations the frequency o f  the CYP2C9* 1 /* I genotype i s  65-70%, the 
C T P_ C9* 1 /* 2  genoty pe is 1 5-20%, the C YP2C9* 1 /* 3  genotype is 8- 1 0%. Poor 
metabol izer genotype frequencies for CYP2C9* 2/*2,  CYP2C9* 3/*3 and 
e yp _ C9*2/* 3 are between 1 and 2% each [63 ] ,  [64 ] .  
1 .5.2 Vita m in K E poxide Red uctase (yKORC l) 
The itamin  K epoxide reductase VKOC 1 enzyme is involved in the b iosynthesis of 
V itamin K dependent coagulation factors through the V itamin K regeneration 
process. On the other hand, Vi tamin K plays a key role  as a cofactor in gamma 
carboxylation of several c lotting factors ( I I ,  V I I ,  I X  and X )  and proteins C and S that 
are a l l  i nvolved in coagulation. The Vi tamin K epoxide reductase V KOC 1 enzyme i s  
Warfarin sensi t ive and can  be  i nhib i ted by  preventing the V i tamin K recycl ing 
process [67]-[69] as shown i n  Figure 4 .  
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Warfarin inhibits V itamin K recyc l i ng and thus prevent ing the formation of more 
Vitamin K dependent coagulation factors [44 ] .  
The VKORCI gene encodes the vitam i n  K epoxide reductase complex subunit- I ,  a 
smal l  transmembrane protein of the endoplasmic ret iculum. V KORC I [ M I M  
2 1  
60 5.+ 7 J  is the key enzyme or  the V itamin K cycle and the molecular site for the 
acti n of Vi tamin K antagonist ( oumarin ) inc luding Warfarin, Acenocoumarol 
and Phenpr coumon. v. hich are u ed for long-term treatment of thromboembolic 
d i  ea e [ 4'+ ] ,  [ 70 ] .  
I t  ha been kno\\ n D r many years that the action of Warfarin involved V itamin K yet 
without fu l l  under tanding of the exact nature of its involvement unt i l  2004 . The 
exa t molecular target or Warfari n \ as di scovered by two independent re earch 
group \\ hen they found a protein that \Va later named as Vitamin K epoxide 
reducta e complex ubunit 1 (VKORC 1 )  [68] ,  [ 7 1 ] .  This gene IS located on 
chromo ome 1 6p 1 1  a shown in  figureS .  
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Figure 5 .  Chromosomal location of VKORC I  gene on the short arm of 
chromosome 1 6. [72 ] .  
The first group of researchers, L i  and col leagues tested the abi l i ty of candidate genes 
to i nhibi t  v itamin K epoxide reductase (VKOR) act ivity in human cel l s  by using 
short i nterfering ( si RNA) pools against these genes to observe gene activity.  L i  and 
col leagues expressed the gene in i nsect cel l s  and described the gene as coding for a 
1 63 -amino acid protei n  with 3 exons. They also showed that the protei n  contained 1 
to 3 transmembrane domains and 7 cysteine residues, 5 of which are conserved 
among human, mouse, rat, zebrafish, Xenopus, and Anopheles [68] .  
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In arne the year. Ro t and col league c loned the VKORC 1 gene and described i t  as a 
gene encoding a protein of 1 63 amino acids ith a mass of 1 8KDa [69] .  It was 
mainl  e, pres ed in  fetal and adult l i vers and to a 1 sser extent in  fetal hearts, 
kidneys. l ung , adul t  hearts and the pancreas. The nzyme is associated with the 
endoplasmic ret iculum [ 7 1 ] .  
Rost col league a l  0 tudied the in olvement of VKORCI in the combined deficiency 
of i tamin-K-dependent c lotting factor type 2 (VKCFD2; OM I M  607473) ,  and 
resi tance to C umarin oral ant icoagu lant drugs ( Warfari n  resi stance, WR; OMIM 
1 22700) .  They found that i t  correlated with pathological condit ions and Warfarin 
re i tance [69 ] .  I n  the rat, four heterozygous missense mutations in  VKORCl were 
reported in Warfarin resistant cases. I n  addit ion, one homozygous point mutat ion in 
exon 3 has been found i n  two w1felated index cases of a combined defic iency of 
vitamin K-dependent c lott i ng factor type-2 ( V KCFD2) [ 69] . 
They also studied the over expression of wi ld-type VKORCl and the form carrying 
the VKCFD2 mutation and noticed a marked increase in V KOR act ivi ty and 
i ncreasing V itamin  K production by approximately 1 4  to 2 1  t imes compared with 
untreated or mock-transfected cel l s  [68], [69] .  These discoveries helped in the 
understanding of Warfarin  resistance in  humans and rodents. 
The purification of recombinant human V KO RC I protein  from baculovirus-infected 
i nsect cel l s  was reported in by Chu who demonstrated that it was possible to convert 
V itami n  K epoxide to V itamin K; and V itamin  K to reduced V itamin  K through the 
enzymatic function of a single VKORCI polypept ide [ 73 ] .  It was thought that 
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K R 1 \Va subunit 1 f the enzymatica l l  functional complex invol ed in 
Vitamin K recyc l ing. I Iowever, it \ a found that the gene product of VKORC l was 
enZ)'mati a l ly act ive on it own which led to the infoffi1al short ing of the name to 
V KOR [ 74 ] .  
Genetic variat ions in  VKOR 1 was a sociated with sign i ficant inter- individual and 
inter-ethnic variabi l ity i n  the dosage of Vitamin K antagonist (Coumarin )  [ 7 5 ] .  
tudies o n  T 'KORCI enhanced our under tanding o f  the Vi tamin K c c le and led to 
improved c l in ical practice [ 76 ] .  
1 .6 The G loba l  Preva lence of  the  Cl inica l ly Relevant VKORCl Alleles and 
G enotypes 
I t  is  wel l known that Warfarin dosage and responses are great ly affected by genetic 
variation in  the VKORCI gene. I n  addition, genetic variat ion in this gene resul ts  in 
d ifferent phenotypes such as resistance to Warfarin ( Warfarin resistance, WR) or 
pathological condit ions known as mult iple coagulation factors defic iency type 2 
(VKCFD2) that can cause a rare bleeding disorder [69] ,  [77 ] .  
The d iscovery of a haplotype structure i n  the human genome and the abi l ity to define 
S Ps, fac i l i tated genotyping studies at significantly reduced costs. There is a need to 
take i nto account not only d ifferences between the genotypes of individuals but the 
differences i n  genotypes between different populations to improve health care [ 78 ] .  
I n  Warfarin resistant patients, several rare mutations in  the VKORC 1 gene lead to 
amino acid changes in VKORC I protei ns .  These rare mutations are not reported in  
the general population [ 69 ] .  
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rhe genet ic ba i of the large inter- individual variabi l i ty among Warfari n  patients 
i J1\ e tigated by Ried r, vvh de cribed the coding region variants of VOR 1 that are 
highly detrimental and cannot explain Warfarin dosage variation [ 79 ]  . 
I n  add ition. a study \\ a conducted to determine whether polymorphisms in  non­
coding regions of the f'KORCl contribute to variabi l ity in  the maintenance dose of 
Warfarin and found that Ps in non-coding regions are assoc iated with Warfarin 
d sage aero the nonnal dose range ( 2  to 1 0  mg per day) [ 79 ] .  This opened the 
door to further nldy other regulatory polymorphisms in the VKORCl that could 
po ibly change Warfarin do age requirements. Consequently, SNPs in the VKORCl 
non-codino region were found in various populations [ 79] ,  as i l l ustrated in  figure 6 .  
rs9923231 rs7294 
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Figure 6. VKORCl gene structure with the relevant non-coding variants. 
The mechanism of how these SNPs in non-coding affect Warfarin dosage variab i l ity 
were thought to be through the effect on the m RNA levels  [ 79] . 
The first S P (C6484T, rs993443 8 (608547.0008)  or 1 1 73C>T) was reported to 
associate with low Warfarin doses. This SNP i s  located i n  the fi rst intronic region of 
the VKORCl gene and the wi ld type C/C genotype requires significantly higher 
doses compared to the TIT genotype [43 ] .  
Thi variant is in  near perfect l i nkage di equi l i brium with promoter region variant 
3673A (r 99�323 1 )  [ 43 ] .  ince the frequency of 6484T is approximately simi lar, 
if not identicaL to the frequenc of G3673A, som researchers consider this variant 
inert but it i '  sti l l  u ed  frequentl in haplotype deteml ination of the VKORCI gene as 
marker of P [ 5 2 ] .  
Warfarin en i t i  i ty In pat ients with lower doses i s  frequently associated with 
promoter region single nuc leotide polymorphism - 1 639G-A ( 608547.0006). On the 
other hand, T 'KORel ariant rs7�94 (G904 1 A ), or 3 730G>A are reported to be 
a sociated with Warfarin resistance in patients who need higher doses compare to the 
\vi ld  type [ 66 ] .  
Tv,:o Ps in the non-coding region of the VKORCI gene, rs9934438 (608547.0008) 
and rs992323 1 (608547.0006) were the best predictors of Warfarin dosage through 
tran criptional mechanisms that alters expressions of the Warfarin target receptor 
T KORCl [ 79]-[ 8 1 ]  
The- 1 639G-A (rs992323 1 )  variation i s  assoc iated with lower Warfarin dosages, 
Warfarin sensit iv i ty and higher risks of bleeding [66 ] .  I nd ividual s  with the AI A 
genotype (group A,  haplotype 2 *  mainly) required a lower dose than those with the 
AlG or GIG genotypes. The G al lele comes with a 44% increase in act iv i ty when 
compared with the A al lele [ 82 ] .  
The rs7294 ( G904 1 A) ,  is a variant associated with h igh warfarin dosages that occurs 
at the 3 'UTR of VKORCI gene [43 ] ,  [ 8 3 ] .  I t  does not usual ly occur with the 
1 1 73C>T and 3673G>A variant a l le le haplotype [43 ] .  
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A patient with ( rs992323 1 )  and 1 1 73T ( rs9934438) variant al le le was repolied to 
have a low do e of about 24-26 mg/we k while patient with \ i ld  type required a 
do e of 36mg/\ eek [26] .  
A high do age reported for patients with (r 7294) a l le le variants of approximately 40 
mg/\ eek a a mean dose [26 ] ,  [83 ] .  Th is indicates the effect of T KORCl in  non­
codino variant on Warfarin pharmacodynamics studies that conc l uded that VKORCI 
variation can explain 25% of the variabi l ity in Warfarin dosage [ 79 ] . 
A sign ificant cOlTelation of the rele  ant SNPs in the VKORCl with approximately 
30% of Warfarin dosage variation has been determined in a genotyping study of 20 1 
patients using Warfarin. These findings indicate that the VKORCI genetic variation 
p lays a greater role  in dose requirements compared to C YP2C9 which explains only 
1 2% of the variation in dose requirements [26] .  SNPs in  non-coding regions of the 
VKORCl gene c lassify Warfarin pat ients according to thei r  required dose of 
Warfarin to safely achieve the target I N R  [79] . 
Accord ing to this c lassification, patients with SNP (rs992323 1 )  have low Warfarin 
dose-requirement with approximately 2 . 7  mg per day for the AI A genotype that is  
most ly  d istributed in  Asian Americans. H igh dosage groups with rs7294, AlA 
genotype need 6 .2  mg per day which is widely d istributed among African Americans 
and an intermediate dose of 4 .9  mg per day for patients with heterozygosity in both 
SNPs (rs7294 and rs992323 1 )  [ 79 ] .  There are continuous efforts to ident ify VKORCl 
haplotypes but the nomenclature is sti l l  varied [ 79 ] .  
1 . 7 \Va rfa rin  U age i n  the  U A E  
There are a l i mit d number o f  c l inical research tudies on Warfarin usage in the UA 
and no phannacog netic studies so far. There wa a study in 20 1 2  conducted in AI­
in to evaluate pati nt and staff compl iance with Warfarin usage guide l ines and to 
a e the overa l l  practice and patient outcome [ 84 J .  The authors reported that at AI-
in l lospital. each year there are 800 cases (-27 new) of pat ients on Warfarin 
inc luding Emiratis and e. patriates. I ndication for Warfarin usage among those 
pat ient \vere ' 5°1> for atrial fibri l l ation, 28% for deep vein thrombosi s, 20% for 
pro thetic heart valves and 1 2% for stroke and di lated cardiomyopathy. 
The author found that regular INR monitoring wa canied out for only 23% of the 
pat ient . They also found that 73% of the patients had a stable I N R  while 20% had a 
high INR and 7% had lower values than the therapeutic target. 22% of patients have 
been admitted to the emergency ward from Warfarin patients with 9% of the cases 
unrelated to Warfarin use. I n  addit ion, side effects such as abnormal bleeding have 
been frequently reported among patients with a high INR.  Furthermore, hematemesis 
\vas reported for 25 . 3%, shaving cuts for 2 l . 8%, bleeding gums for 1 9 .9%, bleeding 
\\"ound for 1 4 .6% and melena in 1 1 . 3% of the patients [ 84 ] .  
A lack of  genetic studies re lated to  Emiratis on  Warfarin prompted us  to  carry out 
this project .  
C H  PTE R  2 :  ST U D Y  R AT I O  A L E, A I M  A N D  OBJECT I VE 
2 . 1 Ration a le 
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Warfarin is  a drug with a I \v therapeutic index where smal l  dose changes ma re ult  
1 11 ide effect or treatment fai l ure.  I t  i wel l  knO\ n that the genetic makeup 
f the individual contributes to the ir response to medication inc lud ing Warfarin .  A 
ign iflcant propo11 ion of patient receiving the standard dose of Warfarin may e ither 
not re pond to treatment or exhibit  b leeding as a side effects. Genetic ariat ions in 
the 1'KORC J gene play a major role in  Warfarin  dosages and are responsible for 
about 30°'0 of the dose variation. Therefore, it can be considered to be the major 
genetic determinant. Despite their importance for determining the opt imal start ing 
do e for pat ients. no genet ic studie have been caIi1ed out on Emiratis in re lations to 
Warfarin u e. Therefore, the purpose of thi thesis is to start to fi l l  this gap in our 
knowledge for the local Emirati population. 
2.2 A i m  and Object ives 
2.2 . 1 A i m  
I dent ify the a l leles and genotypes frequenc ies among Ern i ratis for two important 
SNPs (rs992323 1 and rs7294) in the VKORC 1 ,  the gene encoding the cel l ular target 
for Warfarin treatment .  
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2.2.2 Object i  e 
To achieve the above aim, the thesis object ive are : 
1 .  Recruit and btain blood amples from healthy Emirati donors and patients 
recei\  ing Warfarin as part of their healthcare. 
_ .  I olate and quantify genomic DN from each subject using standard molecular 
techniques. 
3. Genotype tho e samples for two S Ps, rs992323 1 and rs7294 NPs, In the 
r 'KORC J gene u ing PCR and direct anger D A sequenc ing. 
4 .  Determine the SN Ps al le le and genotype frequencies among heal thy Emiratis 
subject and patients recei ing Warfarin. 
5 .  Correlate the determined al lele and genotype frequenc ies with drug response in 
patients. 
6. Generate genetic data that might be deposited! shared with hea l th care providers in 
the UAE and/or with international databases .  
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C H APTER 3 :  lVIA T E R I A LS A N D  M ET H O DS 
3. 1 Blood a m p l ing 
Blood amples " ere col lected from tv 0 groups: the first group consi sted of 96 
unre iat d E nationals " ho sun red from a coagulation disorder and are being 
treat d with Warfarin as part of their care .  This  group of subject was recruited from 
pati nt attend ing the I R c l inic at Tawam Hospital, A l -Ain, UAE.  The second 
group consi ted of 1 ] 7 heal thy Emirati subjects from AI-Ain and Abu Dhabi .  
Al l  the individuals  had read the i nformation sheet and signed informed consent forms 
to part icipate in the stud . bout 1 0ml  of peripheral venous b lood was col lected. 
F ive ml  of the blood sample was p laced in  an EDT A tube (containing an 
anticoagulant) to be genotyped. The subjects a lso completed a quest ionnaire and 
their medical fi les were reviewed to examine the fulfi l lment of the 
inc lusion/excl usion criteria .  This study protoco l  was carried out at the laboratories of 
the Col lege of Medicine and Health Sciences at UAE University . I n  addit ion, i t  was 
approved by the ethical commi ttee for human research in the AI-Ain District (CRD 
26 1 -Protocol o. 1 3/3 8 ) .  
3.2.  Extraction of  D N A  from Periphera l  Leu kocytes 
Deoxyribonucle ic acid ( DNA) was extracted from an ethylene-diamine-tetra- acetic 
acid ( EDT A)-anticoagulated blood using a whole blood extraction kit (Flexigene 
DNA i so lation kit (250)- Appl ied B iosystems) .  The i solated genomic DNA was 
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stored in  teri le ials at 4 °c unt i l  analyzed. 0 A samples were kept at - 20 °C for 
long te1ll1 torage. 
3.3. Pr imer De ign 
Primer for ampl ify ing the relevant parts of the VKORCl gene were designed using 
primer3 http://pri mer3 .ut .ee and were custom made by Metabion I nc 
(http://yv\\i\v.metabion.com) .  The I i  t of PCR and sequencing primers are l i sted in  
Table 1 .  
S N P  Forw a rd Pr imer Reverse Pri m er 
rs992323 1 3 ' GCCAGC GGAGAGGGAAATAS 3' AGTTTGGACT ACAGGTGCCTS ' 
rs7294 3 ' GGCTTACGC CGTATTC S' 3 ' GGTTCAGACTTGGCTG TTGS '  
Table 1 .  Sequences of the ol igonuceloetide primers used for the PCR amp l ification 
and genotyping of the two VKORCl SNPs 
3.4 Polymerase Cha in  Reaction (PC R) 
PCR ampl ification ( thermal cyc l i ng) conditions were as fol lows: a single 
denaturation cycle of 5 m inutes at 95 °C fol lowed by 40 cycles of 95 °c for 2 
m inutes. The exact anneal ing temperatures and t imes are l i sted in  table 2 and then at 
72 °C for 2 minutes. This was fol lowed by a single cyc le  of 7 m inutes at 72 °C .  
Primer nnea l ing Anneal ing Time Product lze ame Temperature (uC)  ( ec)  (pb) 
r 992323 1 5 8  30 290 
rs7294 60 45 659 
Table 2. nneal ing temperatures optimization and expected product lzes. 
3.5 A n a ly is of  peR A m pl icons by Aga rose Gel E lectr"ophoresis . 
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The two V KO RC I spec i fic products (ampl icons) from each subject were separated 
by 0 .6% agarose gel e lectrophoresis to ensure a good DNA qual i ty was produced 
before sequenc ing. The promoter region S P ( rs992323 1 )  is expected to produce 
D band (A)of 290 bp whereas SNP ( rs7294) wi l l  give a Size of 659 bp (B)  as 
pre ented in F igure 7 
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F igure 7 .  garose e lectrophoresis analysis of representative peR reactions for the 
two P and primers of experiment and the ir  approximate base pair sizes. 
3.6 DNA Seq uencing 
D was sequenced u mg a dideoxy sequencmg (chain  termination of Sanger) 
method \ ith a 3 1 30Xl  Genetic Analyzer (appl ied B iosystems).  The procedure 
invol ed c leaning up the pe R reactions using an Exo-SAP- IT treatment prior to 
anger D A sequenc ing. 
3.6. 1 E xoSa p- IT Treatment 
The ExoSAP-IT was used for c leaning up the peR products. This technique has 
been shown to be suitable for c leaning up peR products of less than 1 00 bp to over 
than 20kb without any sample loss, by removing the unused excess primers and 
nucleotides through a degradation by enzyme action. The method in this experiment 
was carried out by 1 . 25 j-ll of purified peR product to undergo enzymatic purification 
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\\ ith 0 .5  II I of an P -IT enzyme mixture at 7 °c for 1 5  minutes. This was 
G l lowed by heat ing at 80 0 for 1 5  minute t inacti ate the exonuclease and SAP 
enz) me . 
3.6.2 DN Cycle Sanger Seq uenc ing 
The c c le  equencing was carried out by preparing a equencing mix containing 1 � l  
( 3 .2 pm 1)  of sequenc ing primers, 4�d of read reaction premix 2 .5X ( Big Dye 
Tem1inator Cycle equenc ing Kit  Applied Bio ystems), 1 III of B igDye Terminator 
\' . 3 . 1 sequenc ing buffer ( 5  ) and 20ng/ ml  template. mi l iQ water was added to fonn 
_O�d reaction. The tubes 'were placed in  a thennal c c ler and an init ia l  denaturation 
tep was perfonned with a rapid th el111 a I ramp to 96 °C for 1 minute, then the 
fol lo\ ing steps were repeated up to 25 cycles :  
• A.rapid thennal ramp to 96 °c (96 °c for 1 0  seconds). 
• A rapid thennal ramp to 50 °c (50 °c for 5 seconds).  
• A rapid thel111al ramp to 60 °c (60 °c for 4 mi nutes) .  
• A rapid  thennal ramp to 4°c .  
• Puri fication of the sequenc ing products .  
3.6.3 DNA Seq uencing P u rificat ion Step 
If  the dye tel111i nators are not removed completely before the e lectrophoresis step, the 
signal from the dyes wi l l  be obscured due to an excess of DNTPs. This method is 
suitable when using Big Dye Tenninators v3 . 1  as i t  produces consistent signa l ing 
and i t  i s  good at getting a 20�1 sequenc ing reaction in  96-we l l  reaction plates 
fol lowing a brief spinning after removing the reaction from the thennal cycler. 5�1 of 
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1 25 mm EDT is added to the 60 �l of 1 00% ethanol  in each \vel !  and the mixture i s  
ealed and in  erted 4 t imes before being incubated for 1 5  minutes at room 
temperature. Thi was then immediate ly centri fuged at 3000 xg for 30 minutes 
( igma 2- 1 6  pk) and the plate \ as in  erted and spun at up to 1 85 xg then removed 
from the centr ifuge. 60 �1 of 70% ethanol \ as a lso added to each wel l  then spun 
again at 1 650 x g for 1 5  minutes wi th the centri fuge set at 4 0c . This  was fol lowed by 
inversion and spilming up to 1 85xg for 1 minutes before remo al from the 
entri fuge. 
3.6A Formam ide T rea tment  
H i-Di Formamide is  a highly deionized fonnamide fommlated with stab i l izers and 
read for use as an i njecting olvent in D A analysis methods. The samples were 
resuspended i n  1 5  �Ll forrnamide ( Hi -Di  TM forrnamide, Appl ied Biosystems), 
denaturated at 95 °C for 2 minutes and then kept on ice for 2 minutes until 
sequenc l l1g. 
3.6.5 Seq uencing Data I nterpretat ion  a nd Genotype Cal l ing  
For each patient the chromatograms of the nuc leotide sequence were al igned with the 
original VKORCl sequence ( ENST00000394975)  using the chromas l i te program in  
order to  detect the presence of  SNPS/mutations a s  wel l  a s  to  define each patient ' s  
genotype. 
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3.7 tat i  t i ca l  n a ly i 
P � and raph Pad program \\ ere u ed to apply selected statistical anal S IS ;  we 
u ed chi- quare te t for non-parametric ariables to compare between frequency 
r LIlts. \\ h i le  mult ipl l i near regre ion model , A OVA and Speam1aJ1 analysis 
\\ ere u d to tudy dose-genotype re lation . 
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C H A PT E R  4 :  R ES U LT 
..t. 1 De cr ipt ion of  tudy am ple 
Thi study involved two groups of U E nationals .  The first group inc luded 1 1 7 
unrelated health ubjects as contro ls  and the econd group consi sted of 96 patients 
who were on Warfarin treatment for at least two months. Patient characteristics are 
w11 lnnrized in table 3 .  
Median Age 64 year 
Average Age 59 year 
Age 
Standard Deviation (SD)  1 9 . 73 year 
Gender Male 48(50%) 
Female 48(50%) 
Atria l  Fibri l lation 46(48%) 
Deep Vein Thrombosis 1 5( 1 6%) 
Valve Replacement 26(27%) 
I ndication of 
Ant iphosphol ip id Syndrome 3(3%) 
Cardio Vascular Shunt 1 ( 1  %) 
Warfarin 
Cerebe l la  Ataxia 1 ( 1  %) 
Artery Thrombosis 1 ( 1  %) 
Pulmonary Embol ism 2 (2%) 
Valve Disease 1 (1 %) 
Table 3 .  Characteristics of the recruited patients 
I nformed consent was obtained from each part ic ipant. This  study was approved by 
the ethics committees of each partic ipat ing i nstitution. Patient infOlmation ( indicators 
of Warfarin use, maintenance doses and I N R  values etc . )  were col lected from 
Tawam Hospital medical records as of 23/09/20 1 4. 
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I n  this tudy " e recrui ted equal numbers of pat ients of both genders : 48 females and 
-+8 male . The mean age was 64 and the median age wa 59 .  The age ranged from 1 7  
t 99 year with a tandard de iation of 1 9. 73 year . 
Warfarin was prescribed for pat ients for di fferent pathological conditions with Atrial 
F ibri l lation (AF I B )  at 48% ; Deep Vein Thrombosis ( DVT) at 1 5%; Antiphoshol ipid 
) ndrom ( P ) at 3%; fter Mitral Val e Replacement (MVR) and Aort ic Valve 
Replacement (A V R) for � 7%; 2% for Pulmonary Embol ism ( PE) ,  whi le Valve 
Disease, rterial Thrombosis, Cerebel la Ataxia, Cardio Vascular hunt each 
con t i tut d 1 % of the total u e of Warfarin. 
The target I N R  range for 67% of the pat ients was 2 . 5 -3 . 5 ;  32% with an INR target 
range of 2 -3 where only 1 % ha e a target range of 1 . 5-2 .  
The average Warfarin dosage of patients was 4 .7 mg/day with an D of 2 .47 and a 
median dose of 4 .5  mg/day. The highest dosage was 1 5  mg/day and the minimwn 
dose was 0.5 mg/day. 
-t.2.  VKORCl Genoty pe and  A l lele Freq uencies 
sing peR ampl ification and d irect D A sequenc ing, we genotyped each subject 
from both groups for two r 'KORCl gene variants relevant to Warfarin dosage. The 
two variants are the promoter region variant rs992323 1 and the 3' UTR region 
variant rs7294, as l i sted in table 4. 
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ucleotide posi tion Nucleotide Gene region 
S p change 
Gen mic cD 
r 99232 1 3673 c .  - 1 639 G>A Promoter 
rs7294 904 1 492+ 1 34 G>A 3'-region 
Table 4. Description of the tudied polymorphi ms (SN Ps) of the VKORCl gene. 
(cD : coding D , rs : reference ubgroup) 
R 7_94 wa elected as per the l i terature due to its key role in Warfarin resistance 
ca e . whi le variant P r 992323 1 was e lected as per the U A Food and Drug 
Administration (FDA) recommendations [ 8 5 ] ;  as shown in table 5 .  
Drug L ink i n  Referenced Subgroup Labe l i ng Sections with Drugs FDA Phannacogenomic I nfonnation 
Warfarin VKORC 1 rs992323 1 Dosage and Administration 
A al lele carriers C l inical Pharmacology 
Table 5 .  Food and Drug Administration (FDA) labe l ing recommendations for 
Warfarin 
4.2 . 1  Deter m ination of the  VKORCl r 992323 1 Genotypes a n d  A lleles 
Freq uencie 
T XORCl rs992323 1 SNP genotype and al lele frequencies anlong patients and 
contro ls  are presented in tab le  6 .  
40 
ontrol Pat ients UAE 
= 1 1 7  =96 =2 1 3  
(%) (%) (%) 
GG 30(25 .6 )  24(25 )  54(25 )  
G not pes G 58(49.6) 46(47 .9 )  1 04(49) 
AA 29(24 .8 )  26(27 . 1 )  55 (26)  
l Iel s G 1 1 8 (50 .4)  94(49) 2 1 2(49 .8 )  
A 1 1 6(49 .6)  98(5 1 )  2 1 4( 50 .2)  
Table 6 .  Genotypes and a l le les frequencies among pat ients and controls for 
r 992323 1 
patients) 
indicates the total number of study subjects in  both controls  and 
We compared the percentage of the three genotypes (GG, GA and AA) between both 
groups (control and patients) as l isted in table 7 
Controls  Patients 
Genotype n= 1 1 7  n=96 
GG 55 . 6% 44.4% 
GA 55 . 8% 44.2% 
AA 52 . 7% 47 .3% 
Table  7 .  Percentage of rs992323 1 SNP Genotypes among both groups, controls and 
pat ients. 
(N indicates the total number of study subjects in both contro ls  and patients) 
There ar no tati t ical l igni ficant d ifference in the prevalence of GG. GA. 
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gen type for rs992323 1 between the contr I group and the patients. We used a chi-
quar te t to inve t igate (chi-square= 0. 1 459. df = 2, p-value = 0.9296). The aim of 
this te t \ a to inve t igate if there \ a a d ifference in  genotype frequencies between 
healthy control group and pat ients. 
The gen type frequencies of rs992323 1 in  the 2 1 3  UAE part ic ipants are presented in 
( table 6) .  They how that the genotypes GG and A have simi lar distlibutions of 
2 �o o and 26% respecti e ly .  On the other hand, the heterozygous genotype GA 
fr quency was 49 %. The al lele frequenc ies for r 992323 1 ariants are presented in  
Table 6 wi th a lmost equal frequencies of 49 .8% for the G a l lele and 50 .2% for the A 
al le les. T' KORCl rs992323 1 S P genotype frequencies among patients and control 
subject are presented graphical ly in F igure 8 .  
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Figure 8 .  Graphical  presentation of genotype frequencies among patients and control 
for rs992323 1 .  
42 
In addit ion, \ve compared the re ult from thi study to data from other populations 
a Ii ted in table 8 
AE audi I ran Ch ina Caucasian l nd ian 
J 'KORCl 
n=2 1 3  n= 1 3 1  n=8 1 n= l 78 n=22 n=43 
p Genotype 
[86]  [ 87 ] [88 ]  [89]  [ 90]  
GG 25  3 7 .4 1 5 . 8  0.6 3 1 . 8 83 . 8  
G- 1 639A 7 
G 49 39 .7  57 . 1 1 5 . 7  50.0 9 .50  
4 
AA 26 22 .9 26.9 83.7 1 8 .2 6 .80 
8 
I le les G 49.8 57 44,4 8 .42 56.82 88 .4 
Frequency A 50 .2  42 .7  55 .6  9 1 .5 7  43 . 1 8  1 1 .6 
Table 8. Etlmic distribution of 1's992323 1 Genotypes and a l le les 111 vanous 
populations. 
The graphic representation of ethnic distributions of rs992323 1 genotype 
frequencies is shown in figure 9 and al lele frequenc ies in figure 1 0  
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Figure 9 .  Ethnic distribution of r 992323 1 genotypes 
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e used a chi-square te t ( nonparametric t t for di crete variable ) to compare the 
d ifference between the al le le frequencies in popu lations hown in table 8: the value 
of p<0.05 wa c n idered as tati stical ly  signi ficant. tati tical analyses were 
perfOnlled appl ing the Graph Pad program. The UAE population when compared to 
the hinese Population had a p a lue of <0.00 1 .  The UAE population when 
c mpared to the I ndian Population had a p of <0.00 1 .  For the other popUlat ions, there 
\\ ere n sign i fIcance d ifference in  a l le le frequencies 
4.2.2 Dete r m i n a t ion of the V KORCl rs7294 G e notype and A l lele Freq uen cies 
l TKORCl rs7294 P genotype and al le le frequenc ies among pat ients and control 
subj ects are pre ented in table 9 . .  
Controls Patients UAE 
S P Genotype N= 1 1 7  N=96 N=2 1 3  
(%) (%) (%) 
GG 54(46 .2 )  40(4 1 . 7 )  94(44) 
G904 1 A  
GA 46(39 .3 )  48(50) 94(44) 
rs7294 
AA 1 7( 1 4 . 5 )  8( 8 . 3 )  25 ( 1 2 ) 
A l le les G 1 54(66) 1 28(66 .7 )  282(66) 
Frequency A 80(34)  64( 33 . 3 )  1 44( 34) 
Table  9. Genotype and Al le le frequency for rs7294 for controls  and patients. 
We compared the percentage of the three genotypes (GG GA and AA) for rs7294 
between both groups (control and patients) as l i sted in table 1 0 . 
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Controls Patient 
G notype 
n= 1 1 7  n=96 
GG 5 7.4 % 42 .6 % 
GA 48 .9 % 5 1 . 1  % 
68 .0 % 32 .0 % 
Table  1 0 . Percentage of  r 7294 SN P genotypes among both control and pat ient 
groups. 
(N= total number of ubjects in both control and patient groups) 
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Figure 1 1 . Graphic  presentation o f  genotype frequencies among patients and control 
subjects for rs7294 . 
The genotype frequency of rs7294 for the total study sample of 2 1 3  UAE locals i s  
shown i n  table 9 .  I t  shows d ifferences i n  the distribution of the homozygous GG and 
AA genotypes with frequencies of 44% and 1 2%, respectively. On the other hand, 
the h leroz gous G genotype 
46 
I II equal di  tribution with the homozygous 
genol) pe 44 %. l le le frequenc ies are hown in table 9 with the G a l le le being 
pre nt at frequenc of 66% ,while the al le le i present at a frequency of 34%. We 
compared resul ts from thi study to data from other populations as l i sted in table 1 1 . 
AE Chi nese Caucasian I ndian 
VKORCI Genotype n=2 1 3  n=55 1 n=23 n=43 
p [ 9 1  ] [ 89 ]  [90 ]  
GG 44 8 l . 3 43 . 5  8 . 1 
G904 1 A  
GA 44 1 8 .3  47 .8  1 8 .9  
rs7294 
AA 1 2  0 .4 8 . 7  73 
A l leles G 66 90. 5  67 .4 1 8 .6  
Frequency A 34  9 . 5  32 . 6  8 1 .4 
Table 1 1 . Ethnic d istribution of the rs7294 genotypes and al le les frequenc ies. 
Graphic representation of etlmic d istribution of rs7294 genotype frequencies I S  
shown i n  figure 1 2  and the al le le frequencies in  figure 1 3 . 
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Figure 1 2 . Ethnic d istribution of  rs7294 genotypes 
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Figure 1 3 . Ethnic d istribution of rs7294 al le les. 
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We I I  ed a chi-square te t ( n  nparametric test for discrete variables) to compare the 
di frerence behveen 1h a l le le frequ ncies in populations a shown in table I l .The 
v alue f p<O.05 " a  c n idered as tatistical ly signi ficant. tatistical analy es were 
performed applying the Graph Pad program. 
The E population " hen compared with the I nd ian and Han-Chinese population 
had a p<O.OO l .There \\'ere no signi ficance d ifferences in a l le le frequencies with 
European population . 
.t.3 T h e  R 992323 1 a n d  Rs729.t VKORC1 Vari a n t  Gen otypes Associated w i t h  
\Va rfa ri n  Do e s  A m o n g  E m i ra t i  P a t i e n ts 
A pearman con'elation coeffic ient statistical analysis was selected to test the 
correlation coefficient in each NP ,  
We used the Graph Pad to  study the correlation between each SNPs and the dai ly 
maintenance Warfarin dose for patients inc luded i n  this study. I n  summary, both 
Ps shows significant correlat ions with dosages ( P<O.05) as shown in figures 1 4  
for rs992323 1 genotypes and figure 1 5  for rs7294 genotypes. 
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Figure 1 4 . peruman Correlation Coefficient between rs992"' 23 1 genotypes and dai ly 
Warfarin dosage. 
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Figure 1 5 . Spearman Correlation Coeffic ient between rs7294 genotypes and dai ly  
Warfarin dose. 
50 
e u ed  a catter Plot to  graph ical J represent each genotypes relat ion to dosage. 
B th P wer correlated ign i ficantl to dai ly Warfarin dosage ( P-value<0.05)  as 
hO\\l1 in figures ] 6 and 1 7 . 
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Figure 1 6. Scatter Plot representation of rs992323 1 genotype relation to dai ly 
Warfarin dose ( * * *  means P-value < 0 .05) .  
The GG genotype shows a higher dosage compared to GA and a lesser dosage to the 
AA genotype . Whi le for rs7294 the higher dose is associated with the AA genotype. 
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Figure 1 7 . catter Plot representation of rs7294 genotype relat ion to dai ly Warfarin 
do es ( * * *  means P-value < 0 .05 ). 
I n  addition, we used a Boxplot method to represent patient dose variation in  relation 
to genotype and to sho\ the d ispersion ( the spread) of doses among each genotype 
for Ps. This data i s  shown in  figures 1 8  and 1 9 . 
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SNP rs9923231 genotypes vs.  warfarin dose 
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Figure 1 8 . Boxplot of mean dai ly  Warfarin doses for d ifferent VKORC 1 genotypes 
( P rs992323 1 ) . 
The horizontal l i ne indicates the median; the box covers 25-75% percenti les. Points 
outside this show up as out l iers. In a l l  96 i nd ividuals  were genotyped for rs992323 1 
genotyping. The maintenance dose of Warfarin was related significant ly  to genotype 
since AA genotype requi red a lesser dose compared to the i ntermediate dose for a 
GA genotype and a relatively h igher dose compared to the GG genotype. 
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S N P  rs7294 genotypes vs. warfa ri n  dose 
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Figure 1 9 . Boxplot of mean dai ly  Warfarin doses for d ifferent VKORCl genotypes 
(SNP rs7294) .  
The horizontal l ine indicates the median, the box covers 25-75% percenti les. Points 
outside this show up as out l iers. In al l 96 i ndividuals were genotyped for rs7294 
genotyping. The maintenance dose of Warfarin was related significantly to genotype 
s ince GG genotypes required a lesser dose compared to an intermediate dose for GA 
genotypes and a relatively higher dose for AA genotype carry ing patients. 
Furthermore, we used a multiple l iner regression analysis, where daily Warfarin 
dosages i n  m i l l igrams (mg) was the dependent variable  and the genotype was an 
i ndependent variable and contro l l i ng for other factors such as age and gender. Using 
VKORCl rs992323 1 genotypes, age and gender. 
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l i near regrc sion anal)' i how that there is sign ificant relationship between the 
rs992323 1 P genotype ( A G and GG). 
The average dose for genotype is (2 .6 1 mg /day D 1 .022), for the GA 
gen type it i (- L74 mg/da D 1 . 72)  and for GG genotype it is ( 7  mg/day SD 2 .796). 
the a\'erage age of pati nts \ as 59 ( D 1 9) .  
We found that there v as a sign ificant relationship between age and dosage ( P-value 
< 0 .0 1 )  but to a Ie ser extent than for genotype whi le no relationship with gender to 
dai ly  Warfarin dose ( Po. a lue = 1 ) . This data is shown in table 1 2 . 
Variable Dai ly dose P val ue 
AA < 0 .00 1 
GA < 0.00 1 
GG < 0.00 1 
Age < 0.0 1  
Gender 1 
Table 1 2 . Mult iple l i near regression models  with rs992323 1 genotypes, age, and 
gender. 
( M ult ip le R-squared : 0.477, adj usted R-squared:  0 .454 1 degree of freedom ( DF) :  9 1 ,  
po. a lue :  3 . 5 1 8e- 1 2 . F-stat ist ic : 20 .75)  
For rs7294 we also used a mult iple l i near regression model and results are shown in  
table 1 3  
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Factors Dai ly dose P-Value 
GG >0.00 1 
GA >0.00 1 
AA >0.00 1 
Age >0.00 1 
Gender 1 
Table  1 3 . Mult iple l i near r gression models  \ ith rs2794 genotypes, age, and gender. 
( l u l t iple R- quared: 0.2797, adj usted R-squared : 0 .248,  F-stat ist ic :  8 . 832 on 4, p­
value: 4 .52  -e-06). 
U ing a l i near model \ here dose is  the dependent variable and rs2794 genotypes are 
the independent variable, and control l ing for other factors such as age and gender, we 
found that there was a significant relationship between the rs7294 SNP genotype and 
the dose taken ( P- alue = 0.0003) .  The average Warfarin dose required for the GG 
genotype is 3 . 6  mglday ( S D  2 . 5 )  the GA genotype is 5 . 3  mg/day ( S D  2) and for the 
AA genotype it was 6 . 7  mg/day (SD 2 .6) .  Age significantly correlated to dose (P­
value >0.00 1 )  \: hile gender was found not to be correlated ( P> 1 ) . 
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I le le and genotyp frequ nc ies for P r 992323 1 and r 7294 in the VKOR I 
gene \\ re found to be in  a Hardy-Weinberg equi l ibrium among the study sample of 
2 1 3  1I E nat ional . There \ ere no ign i ficance differences in the prevalence of GG, 
GA and genot pes for r 992323 1 variants between the pat ients and control  
group as determ ined by a chi-square test (p-value = 0.9296) .  imi larly there was no 
ign i fi ant d ifference between the two group for the rs7294 variant (chi -square test 
Cor G , GA and genotypes ( p- alue = 0. 1 842 . This means, as expected, that 
both P di tributed equal ly between control and patient groups without any 
sign i ficant d ifference a soc iated with any pathological condition. 
The genotype frequency for the rs9923 23 1 variant in the total study sample of 2 1 3  
local UAE part ic ipants for homoz gous GG and A are presented in Figure 8 and 
Table 6. They show simi lar distributions of 25% and 26% respectively while the 
di  tribution of the heterozygous GA genotype was higher at 49%. A l lele frequencies 
for rs992323 1 are shown in  Table 6 and i nd icate no d ifferences in G and A al lele 
frequencies at 49 .8% and 50.2% respectively. 
The genotypes frequency for the rs7294 ariant i n  the total study sample of 2 1 3  
subjects i s  shown in  table 9 and indicates some d ifferences i n  the distribution of 
homozygous genotypes (GG and AA) of 44% and 1 2%, respectively, whi le  the 
heterozygous GA genotype i s  in equal distribution with homozygous genotype at 
44%. We found that the a l le le frequency for G ( 66%) more than for the A al le le 
(34%) as shown i n  table 9 .  
Warfarin dosages vary among Emirati patients with doses ranging from 0 .5  mg to  1 5  
mg of Warfarin per day (figure 1 6, and figure 1 7) .  This wide variation in dose 
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r quirements is  a major ju  t i fication for carry ing out th i  type of genetic stud among 
Emirati . Genetic causes are l i kel to be contribution factor in a sign ificant 
proport ion of thi ariabi l ity, a demonstrated by many stud ies on Warfarin  dosage 
[92] .  Genotypes r r J XORC 1 NP con-e late significant I with dai ly Warfarin doses 
according to th re ults of thi study (figures 1 4  and 1 5 ) .  The rs992323 1 and rs7294 
are clo ely associated \\ ilh dosage with a p-value of < 0 .00 1 for both SN Ps ( figures 
1 4  and 1 � ) . Therefore, we can conclude that the r 992323 1 and rs2794 are good 
predictors of Warfarin maintenance dosage as shown in the Boxblot analysis in  
figure 1 8  and 1 9. For the rs992323 1 homozygous AA genotype a smal ler dose is  
requi red (2 .6  mg/day, 0 1 . 022) compared to the heterozygous GA genotype (4 .75  
mg/day, D 1 . 7 ) . A higher dose is required for the homozygous GG genotype ( 7  
mg/day, SD 2 . 7 )  with a P-va lue < 0.000 1 ( 3 . 5 1 8e- 1 2 ) .  
recent study in  Al- Ain evaluated the effects of other factors such as age, gender, 
body mas index ( BM I ), indications of Warfarin treatment, patient compl iance in  
maintain ing stable I R indicators of correct dosage, etc . They found that gender, and 
B M l  have no effect whi le  age, co-morbid status, and compl iance were found to 
sign ificantly affect the coagulation profi Ie of patients [84] . Although age and gender 
both have been studied in  previous studies, we inc luded i t  in  this study to show have 
direct effect on dosage but not on INR .  I n  our study age significantly affected 
Warfarin dosage as demonstrated by the mult iple regression model of analysis (tables 
1 2, l 3 ) .  Gender on the other hand had no significance effect ( table 1 2, 1 3 ) .  
General ly there is  a focus on rs992323 1 ( - 1 639  Gf A)  variant which i s  located at  the 
second nucleotide of an E-box (CANNTG) of the S' untranslated regions ( 5 ' UTR) of 
the VKORCl gene [82 ] .  This variant p lays a key role on the act ivi ty of the promoter 
regIOn r the VKORC J gene and it is  bel ieved to be a cau ati e 
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requirement phenot pes in some patients [ 5 2 ] .  The activity of the G a l le le is 44% 
higher than the A al le le in thi position [ 82 ] .  Polymorph ism in r 992323 1 ( - 1 639 
G/ ) shows an interfer nce with the mRN expres ion in  l iver samples since it is  
a oc iated \: i th variable lev e l s  of mRNA. The A al le le disturbs the binding of 
tran cription factors to the VKOR 1 gene promoter region leading to a decrease in  
active mature copies of the T XORC I  protein activity [ 82 ] . 
cc rding to the l i terature, patients with the G al lele require a dai ly dose of 5 
mg/day compared to 3 . 5 -"' . 7  mg/ day for pat ient with the A al lele [26] .  In our study 
dai ly doses of Warfarin were approximately 2 .6  for homozygous pat ients with the A 
a l le le  and approximately 7 mg/day for pat ients with the homozygous G al lele 
(F igures 1 6  and 1 8 ). 
Another study has reported that patients with the A a l le le have a Warfarin dose 
ranging from 2 .9  up to 3 mg per day, whi le  patients with the homozygous G al le le 
range from 5.5 up to 6 mg/day [ 79] . 
The frequencies of the rs992323 1 ( - 1 639 G/ A) genotypes and a l le les have been 
widely studied in d ifferent populations [ 52 ] .  For example, 90% of the Asian 
population have the A al le le and therefore pat ients of Asian origin require lower 
doses of Warfarin [ 52 ] .  On the other hand, 40% of some caucasian popUlations have 
the A a l le le .  It was postulated that rs992323 1 is the best predictor of Warfarin dose 
requirements especial ly in the i nit ia l  stages of Warfarin therapy [79 ] .  
I t  i s  worth mention ing that the rs992323 1 variant i s  the on ly  SNP mentioned in  FDA 
recommendations for labe l i ng Warfarin leaflets amongst a l l  the other important 
SNPs in the VKORCl gene. However, many studies have shown the importance of 
59 
other n n-coding Ps in  the VKORCl. Howe er, these Ps are most ly in perfect 
l i nkage di  equi l ibrium with r 992323 1 [79 ] .  Ba ed on se eral studies, the FDA has 
recommended genetic te t ing on Warfarin for the VKORC 1, rs992323 L A al lele 
carrier and for the CYP 2C9 gene haplotype 
( http://v,rww . fda. go vi drugsl sc i e nceresearchl researchareasl pharmaco geneti cs/ucm 0 83 
37 .htm) [ 85 ] .  
nother P located 1 11 the 3 'UTR of the VKORC j rs7294 or as it cal led in the 
l i terature G904 1 , or 3 730G>A. I t  is  not corre lated with any other P in 
rheT 'KORCl gene [ 79 ] .  Genera l ly this SNP i not found in the same haplotypes as 
the G3673A. This is the reason for selecting this SN P in  our study al though it was 
not rec mmended b the FDA. Patients with rs7294 alternat ive variants may require 
higher doses of Warfarin [43 ) .  
I n  this current study, rs7294 as  shown in  figure 1 5  and figure 1 7  for the homozygous 
AA genotype. requi red higher doses (6 .7  mg/day, SD 2 .6) ,  while the heterozygous 
GA genotype required 5 . 3  mg/day, (SD 2) a lesser dose was required for 
homozygous GG genotypes (3 .6 1 mg/day SD 2 . 5 )  With a P-value of < 0.000 1 
(0.0003) .  Therefore, findings i n  this study support previously publ ished data 
confirming a higher dose requirement for individuals with the homozygous A al lele 
genotype ( 5 . 7  mg/ day )  [26] . 
I t  was suggested that 6-37% of the variation in  Warfarin dosage among individuals i s  
due to  S Ps in  the VKORCl gene [79] ,  [ 8 1 ] ,  [ 8 5 ] .  I t  was wel l  documented that the 
VKORCl polymorphism highly influences Warfarin dosage and in some cases may 
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cause re i tance at the a l l  Ie in rs7294 variant or en it ivity \ ith al leles of the 
rs992323 1 variant [79 ] ,  [ 8 1 ] .  
Thi is  fir t genetic tud among Emirati regarding VKORC 1 al le le and genotype 
frequenc ie . Our data suggests that P are ery important for Warfarin 
maintenance do age and therefore they are l i kely to be of c l inical  significance 
( Figures 1 4 and 1 5  . 
Di fferent ethn ic groups reqUI re different Warfarin doses. For instance Chinese 
individuals, on average, require lower dose compared to African Americans [93 ] ,  
[94 ] .  
There have been many trials on new medication to replace Warfarin since its 
approval i n  1 954.  This is mai n ly because of the many repolis of side effects observed 
in pat ients receiving this medication. However survei l lance studies on compl ications 
and pham1aco-epidemiology of Warfarin  are not cUlTently avai l ab le in the UAB. 
There i s  genera l ly  a lack of drug-drug and food-drug interaction studies local ly .  For 
instance, it  was not easy to find reported cases of side effects associated with 
Warfarin treatment, such as Inpatient hospital ization due to Warfarin, patient' 
outcomes in selecting a dosage of Warfarin depending on non-genetic factors in 
Emiratis. Our data ind icates that genotyping wi l l  be useful and most probably cost 
effective when i nit iat ing Warfarin treatment. 
The two variants tested are useful but a c learer and more accurate pictu re can be 
observed if other parts of the VKORCl gene and CYP2C9 gene are studied in  more 
depth in Emirati s. It is also important to look at non-genetic factors i nvolved i n  
Warfarin dose requirements among Emirati s  such a s  l i festyle, diet, chronic use of 
6 1  
ther medicati n ,  food upplements and herbal remedies used by the local 
population. 
Our data indicate that pharmacogenetic test ing of rs99232" 1 and rs7294 variants is 
highl re levant to the maintenance of Warfarin dosage among Emirati patients on 
thi medicat ion.  Implementation of genet ic test ing, at least for these two variants, i s  
l i kely to  have a direct effect with potential benefits to  the patients and healthcare 
y tem in  E .  This  i al 0 l ikely to have a d i rect impact on patient safety and 
reduce suffering and cost . 
The e idence provided here demonstrates that genetic factors in  the VKORCl gene 
are ign ificant contributors to Warfarin dosage and, as a resul t  may be employed to 
reduce the risk of developing ide effects such as bleeding or thrombosis. 
Having said that, we bel ie  e that i t  is  important to sequence the rest of the VKORCl 
gene to study the haplotypes and perhaps examine for the presence of private variants 
i n  this gene among Emiratis . I t  is a lso important to study the variants of the CYP 2C9 
gene. 
In conclusion, this i s  the fi rst study reporting the influence of genetic factors such as 
VKORCl polymorphisms (rs992323 1 and rs7294) in Emirati s. We a lso report the 
frequenc ies of a l leles and genotypes of these SNPs al lowing us to compare with 
other populations which might be useful for genealogical studies. 
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